Online citations, reference lists, and bibliographies.
Please confirm you are human
(Sign Up for free to never see this)
← Back to Search

Polyhydroxy Surfactants For The Formulation Of Lipid Nanoparticles (SLN And NLC): Effects On Size, Physical Stability And Particle Matrix Structure.

A. Kovačević, S. Savić, G. Vuleta, R. Mueller, C. Keck
Published 2011 · Materials Science, Medicine

Save to my Library
Download PDF
Analyze on Scholarcy
Share
The two polyhydroxy surfactants polyglycerol 6-distearate (Plurol(®)Stearique WL1009 - (PS)) and caprylyl/capryl glucoside (Plantacare(®) 810 - (PL)) are a class of PEG-free stabilizers, made from renewable resources. They were investigated for stabilization of aqueous solid lipid nanoparticle (SLN) and nanostructured lipid carrier (NLC) dispersions. Production was performed by high pressure homogenization, analysis by photon correlation spectroscopy (PCS), laser diffraction (LD), zeta potential measurements and differential scanning calorimetry (DSC). Particles were made from Cutina CP as solid lipid only (SLN) and its blends with Miglyol 812 (NLC, the blends containing increasing amounts of oil from 20% to 60%). The obtained particle sizes were identical for both surfactants, about 200 nm with polydispersity indices below 0.20 (PCS), and unimodal size distribution (LD). All dispersions with both surfactants were physically stable for 3 months at room temperature, but Plantacare (PL) showing a superior stability. The melting behaviour and crystallinity of bulk lipids/lipid blends were compared to the nanoparticles. Both were lower for the nanoparticles. The crystallinity of dispersions stabilized with PS was higher, the zeta potential decreased with storage time associated with this higher crystallinity, and leading to a few, but negligible larger particles. The lower crystallinity particles stabilized with PL remained unchanged in zeta potential (about -50 mV) and in size. These data show that surfactants have a distinct influence on the particle matrix structure (and related stability and drug loading), to which too little attention was given by now. Despite being from the same surfactant class, the differences on the structure are pronounced. They are attributed to the hydrophobic-lipophilic tail structure with one-point anchoring in the interface (PL), and the loop conformation of PS with two hydrophobic anchor points, i.e. their molecular structure and its interaction with the matrix surface and matrix bulk. Analysis of the effects of the surfactants on the particle matrix structure could potentially be used to further optimization of stability, drug loading and may be drug release.
This paper references
10.1002/JPS.10413
Influence of emulsifiers on the crystallization of solid lipid nanoparticles.
H. Bunjes (2003)
10.1016/j.ijpharm.2008.10.003
Lipid nanoparticles (SLN, NLC) in cosmetic and pharmaceutical dermal products.
J. Pardeike (2009)
10.1016/J.ADDR.2003.12.002
Solid lipid nanoparticles for parenteral drug delivery.
S. Wissing (2004)
10.1002/3527604812
Applied Surfactants: Principles and Applications
T. Tadros (2005)
10.1080/03639040802130061
Lipid Nanoparticles with a Solid Matrix (SLN®, NLC®, LDC®) for Oral Drug Delivery
M. Muchow (2008)
10.1016/S0378-5173(99)00431-7
Influence of spin probe structure on its distribution in SLN dispersions.
P. Ahlin (2000)
10.1007/3-540-47822-1_2
Effects of surfactants on the crystallization and polymorphism of lipid nanoparticles
H. Bunjes (2002)
10.1016/J.IJPHARM.2004.02.032
Development of a controlled release formulation based on SLN and NLC for topical clotrimazole delivery.
E. Souto (2004)
10.1016/S1359-0294(00)00019-4
Polyhydroxyl-based surfactants and their physico-chemical properties and applications
O. Söderman (1999)
10.17169/REFUBIUM-12273
SLN and NLC for topical delivery of antifungals
E. Souto (2005)
10.1016/J.SCRIPTAMAT.2004.12.026
Gibbs-Thomson effects in phase transformations
M. Perez (2005)
10.1016/J.IJPHARM.2006.02.045
Oral bioavailability of cyclosporine: solid lipid nanoparticles (SLN) versus drug nanocrystals.
R. Mueller (2006)
10.1016/S0378-5173(02)00268-5
Incorporation of cyclosporin A in solid lipid nanoparticles (SLN).
E. Ugazio (2002)
10.1016/S0378-5173(02)00180-1
Nanostructured lipid matrices for improved microencapsulation of drugs.
R. Mueller (2002)
10.1016/S0169-409X(01)00105-3
Solid lipid nanoparticles: production, characterization and applications.
W. Mehnert (2001)
10.1016/J.COLSURFA.2007.06.003
Preparation and characterization of monocaprate nanostructured lipid carriers
Xiaohong Lin (2007)
10.1080/1061186021000038364
Drug Targeting by Solid Lipid Nanoparticles for Dermal Use
C. Santos Maia (2002)
10.1080/10915810152902565
Final report on the safety assessment of PEG-6, -8, and -20 sorbitan beeswax.
Lanigan Rs (2001)
10.1016/S0939-6411(98)00074-5
Correlation between long-term stability of solid lipid nanoparticles (SLN) and crystallinity of the lipid phase.
C. Freitas (1999)
10.1016/J.ADDR.2007.04.011
Solid lipid nanoparticles for targeted brain drug delivery.
P. Blasi (2007)
10.1007/s11095-006-9225-9
Cyproterone Acetate Loading to Lipid Nanoparticles for Topical Acne Treatment: Particle Characterisation and Skin Uptake
J. Štecová (2006)
10.1007/s11095-005-7148-5
Solid Lipid Nanoparticles (SLN) and Oil-Loaded SLN Studied by Spectrofluorometry and Raman Spectroscopy
K. Jores (2005)
10.1016/S0939-6411(00)00087-4
Solid lipid nanoparticles (SLN) for controlled drug delivery - a review of the state of the art.
R. Mueller (2000)
Oral insulin delivery by means of solid lipid nanoparticles
B. Sarmento (2007)
10.1016/j.ejpb.2008.09.003
Lipid nanoparticles for parenteral delivery of actives.
Medha D. Joshi (2009)
10.1016/0378-5173(93)90177-H
Investigations on the physical state of lipid nanoparticles by synchrotron radiation X-ray diffraction
K. Westesen (1993)
10.1016/J.JCONREL.2005.09.045
Lipid nanoparticles for skin penetration enhancement-correlation to drug localization within the particle matrix as determined by fluorescence and parelectric spectroscopy.
S. Lombardi Borgia (2005)
10.1080/10915810152902556
Final report on the safety assessment of PEG-25 propylene glycol stearate, PEG-75 propylene glycol stearate, PEG-120 propylene glycol stearate, PEG-10 propylene glycol, PEG-8 propylene glycol cocoate, and PEG-55 propylene glycol oleate.
W. Johnson (2001)
10.1016/j.ijpharm.2008.01.008
Solid lipid nanoparticles for pulmonary delivery of insulin.
J. Liu (2008)
10.1016/J.ADDR.2007.04.012
Nanostructured lipid carriers (NLC) in cosmetic dermal products.
R. Mueller (2007)
Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) -- structural investigations on two different carrier systems.
Anne Saupe (2005)
Solid lipid nanoparticles (SLN) : an alternative colloidal carrier system for controlled drug delivery
R. Mueller (1995)
10.1016/J.EJPB.2007.05.003
In vitro skin absorption and drug release - a comparison of six commercial prednicarbate preparations for topical use.
S. Lombardi Borgia (2008)
10.1080/109158199225620
Final report on the safety assessment of PEG-2, -3, -5, -10, -15, and -20 Cocamine
F. Andersen (1999)
10.1016/J.EJPB.2006.12.004
Solid lipid nanodispersions containing mixed lipid core and a polar heterolipid: characterization.
A. Attama (2007)
10.1016/j.ijpharm.2007.12.004
Size analysis of submicron particles by laser diffractometry--90% of the published measurements are false.
C. Keck (2008)
10.1016/J.JCONREL.2003.11.012
Investigations on the structure of solid lipid nanoparticles (SLN) and oil-loaded solid lipid nanoparticles by photon correlation spectroscopy, field-flow fractionation and transmission electron microscopy.
K. Jores (2004)
10.1016/S0169-409X(02)00118-7
Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) in cosmetic and dermatological preparations.
R. Mueller (2002)



This paper is referenced by
10.1016/j.colsurfb.2012.08.052
Preparation and characterization of Paliperidone loaded solid lipid nanoparticles.
Sacheen Kumar (2013)
10.2147/IJN.S131893
Development of solid lipid nanoparticles containing total flavonoid extract from Dracocephalum moldavica L. and their therapeutic effect against myocardial ischemia–reperfusion injury in rats
Mei-e Tan (2017)
10.1080/10837450.2020.1759630
A promising approach to develop nanostructured lipid carriers from solid lipid nanoparticles: preparation, characterization, cytotoxicity and nucleic acid binding ability
Ezgi Oner (2020)
10.1016/j.ijpharm.2017.03.019
Nanoparticles as safe and effective delivery systems of antifungal agents: Achievements and challenges.
G. M. Soliman (2017)
10.3109/03639045.2016.1151028
Topical delivery of paclitaxel for treatment of skin cancer
Rituraj Bharadwaj (2016)
10.2147/IJN.S61670
Nanotechnology-based drug delivery systems for treatment of oral cancer: a review
G. Calixto (2014)
10.1016/j.ejps.2012.05.010
Are nanostructured lipid carriers (NLCs) better than solid lipid nanoparticles (SLNs): development, characterizations and comparative evaluations of clotrimazole-loaded SLNs and NLCs?
S. Das (2012)
10.11606/T.60.2015.tde-01072015-091103
Influência do ultrassom de baixa frequência associado à hidrogéis na permeabilidade da pele e no tratamento tópico do câncer de pele
T. A. Pereira (2015)
10.1016/j.colsurfb.2017.03.006
Nanostructured lipid carriers of olmesartan medoxomil with enhanced oral bioavailability.
Vikram Kaithwas (2017)
10.3109/03639045.2015.1132226
Effect of liquid-to-solid lipid ratio on characterizations of flurbiprofen-loaded solid lipid nanoparticles (SLNs) and nanostructured lipid carriers (NLCs) for transdermal administration
Aihua Song (2016)
10.1016/J.JTICE.2016.11.010
Evaluation of Glabridin loaded nanostructure lipid carriers
C. Zhang (2017)
10.1007/s12272-013-0154-y
Development and evaluation of glyceryl behenate based solid lipid nanoparticles (SLNs) using hot self-nanoemulsification (SNE) technique
J. S. Negi (2014)
10.22159/AJPCR.2017.V10I2.14835
EFFECTIVITY AND PHYSICOCHEMICAL STABILITY OF NANOSTRUCTURED LIPID CARRIER COENZYME Q10 IN DIFFERENT RATIO of LIPID ALFA CETYL PALMITATE AND ALPHA TOCOPHERYL ACETATE AS CARRIER
Astridani Rizky Nim. Putranti (2017)
10.1016/j.foodchem.2015.12.061
Preservation of anthocyanins in solid lipid nanoparticles: Optimization of a microemulsion dilution method using the Placket-Burman and Box-Behnken designs.
Raheleh Ravanfar (2016)
10.1016/j.ijpharm.2019.118575
Hybrid Ofloxacin/eugenol co-loaded solid lipid nanoparticles with enhanced and targetable antimicrobial properties.
B. Rodenak-Kladniew (2019)
10.1016/j.ejpb.2013.04.020
Drug solubilisation in lipid nanoparticles containing high melting point triglycerides.
P. Wasutrasawat (2013)
10.2217/nnm.12.170
Formulation design and evaluation of quantum dot-loaded nanostructured lipid carriers for integrating bioimaging and anticancer therapy.
Shu-Hui Hsu (2013)
10.1055/s-0043-102404
Development, In Vitro Characterization, Antitumor and Aerosol Performance Evaluation of Respirable Prepared by Self-nanoemulsification Method.
Neda Naseri (2017)
10.1007/978-3-662-47039-8_14
Natural Emulsifiers of the Alkyl Polyglucoside Type and Their Influence on the Permeation of Drugs
I. Pantelić (2015)
10.1080/03639045.2020.1724135
Systematic implementation of quality-by-design (QbD) to develop NSAID-loaded nanostructured lipid carriers for ocular application: preformulation screening studies and statistical hybrid-design for optimization of variables
V. Rathod (2020)
10.1016/J.JDDST.2019.01.040
Resveratrol anchored nanostructured lipid carrier loaded in situ gel via nasal route: Formulation, optimization and in vivo characterization
A. Rajput (2019)
10.1002/jbm.a.34642
Nanoparticle systems as tools to improve drug delivery and therapeutic efficacy.
Deepa Mishra (2013)
10.1007/s11051-014-2782-7
Paclitaxel-loaded lipid nanoparticles for topical application: the influence of oil content on lipid dynamic behavior, stability, and drug skin penetration
Fabiana Vaz Tosta (2014)
10.1016/j.xphs.2018.01.026
Folate-Conjugated Superoxide Dismutase Adsorbed Over Antioxidant Mimicking Nanomatrix Frameworks for Treatment of Rheumatoid Arthritis.
Shikha Srivastava (2018)
10.1016/J.COLSURFA.2016.08.043
Enhancement of stability and controlled drug release of lipid nanoparticles by modified solvent-evaporation method
Sang-eun Lee (2016)
Nanoemulzije dobijene variranjem tipa emulgatora i udela masne faze: Uticaj formulacije i procesnih parametara na karakteristike i fizičku stabilnost
Nebojša D. Ceki (2013)
10.3109/21691401.2014.909822
Nanostructured lipid carriers and their current application in targeted drug delivery
Piyush Jaiswal (2016)
10.15171/apb.2017.008
Vitamin D3-Loaded Nanostructured Lipid Carriers as a Potential Approach for Fortifying Food Beverages; in Vitro and in Vivo Evaluation
M. Mohammadi (2017)
Characterization and stability evaluation of thymoquinone nanoemulsions prepared by high-pressure homogenization Abstract Despite the pharmacological properties of thymoquinone (TQ), its administration in vivo
Z. Tubesha (2015)
Solid Lipid Nanoparticle: A Novel Drug Delivery in Pharmaceutical Science
A. Srivastava (2020)
10.20517/2574-1225.2018.44
Theranostic nanoplatforms for treatment and diagnosis of rectal and colon cancer: a brief review
Y. Gholami (2018)
10.1016/J.JDDST.2019.02.026
Development, in-vitro and in-vivo evaluation of ezetimibe-loaded solid lipid nanoparticles and their comparison with marketed product
Fakhar Ud Din (2019)
See more
Semantic Scholar Logo Some data provided by SemanticScholar